Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of pediatric patients previously treated with dabrafenib and/or trametinib
NL-OMON59609Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabrafenib + trametinib and trametinib in cancer (3 arms), sponsored by Novartis. Primary endpoint: Long-term safety. Started Dec 2022; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON59609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59609.